Methylphenidate HCL ER Tablets Solicitation
Closed Pre-Solicitation Posted
- Solicitation number
- SPE2D2-24-R-0014
- Agency
- Medical Supply Chain Troop Support, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Points of contact
-
- Courtney Hunter-Stangler courtney.hunter-stangler@dla.mil (215) 737-6845
- Jason Wray jason.wray@dla.mil (215) 737-0614
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency (DLA) Troop Support Medical is planning to issue a solicitation for a national requirements contract for Methylphenidate HCL ER Tablets in 10MG and 20MG strengths, packaged in 100-count bottles. This will be a fully competitive, commercial item acquisition under FAR Part 12, establishing a national supply source for the Department of Defense, Bureau of Prisons, Indian Health Service, and Department of Veterans Affairs. The contract will be a firm-fixed price requirements-type contract with a one-year base period and four one-year option periods. Interested parties should submit proposals electronically through the DLA Internet Bid Board System (DIBBS) and SAM.gov, with the current projected solicitation date set for June 2024. Potential offerors can contact Courtney Hunter-Stangler at (215) 737-6845 or Courtney.Hunter-Stangler@dla.mil for any questions or comments.
The solicitation is an unrestricted procurement with no specific set-aside designations. The awarded contract was ultimately given to SpecGx LLC on December 10, 2024, with a total estimated value of $4,154,058.30 over five years. Unit prices are fixed at $47.91 per bottle for 10MG tablets and $49.35 per bottle for 20MG tablets, with estimated annual quantities of 7,091 and 9,951 bottles respectively. Manufacturing will be performed at SpecGx LLC's Hobart Plant in Hobart, NY. The contract performance date is set at 45 calendar days after contract award (or sooner by mutual agreement), with contract prices becoming effective 15 calendar days after the performance date. Distribution will be managed through pharmaceutical prime vendors including Amerisource Bergen, Cardinal Health, Dakota Drug, DMS Pharmaceutical Group, and McKesson Corporation.
Notice text
5 versions
Update #5 · Latest ·
Contract for Solicitation # SPE2D2-24-R-0014 has been awarded to SpecGX under award number SPE2D2-25-D-0003.
Update #4 ·
Solicitation # SPE2D2-24-R-0014 has been extended and it will now close on August 1, 2024 3PM EDT.
Please see amendment P0002 for further detail.
Update #3 ·
It was brought to contract specialist's attention that the solicitation number on the header and on page four of the solicitation required updating. This amendment has been incorporated to reflect this change.
Please see amendment P0001 for further detail.
Update #2 ·
Solicitation attached.
Update #1 ·
The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Methylphenidate HCL ER Tablets. Procurement details follow.
Methylphenidate HCL ER: 10MG and 20MG tablets in 100 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Bureau of Prisons, Indian Health Service and Department of Veterans Affairs customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency.
A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.gov at https://sam.gov. Interested parties should contact Courtney Hunter-Stangler at (215) 737-6845 or Courtney.Hunter-Stangler@dla.mil for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is June of 2024. DLA reserves the right to issue the solicitation before or after the projected solicitation date.
Attachments
| File | Type | Posted |
|---|---|---|
| Award for Methylphenidate ER SPE2D2-25-D-0003 Bi-Laterally Signed.pdf | ||
| SPE2D2-24-R-0014 P00002.pdf | ||
| Revised - Methylphenidate HCL ER Solicitation - SPE2D224R0014.pdf | ||
| Methylphenidate HCL ER Solicitation - SPE2D224R0014.pdf |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity